BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16625854)

  • 1. Biochemical evidence in favor of revising Cortina criteria.
    Webb SM; Sucunza N; Barahona MJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):84-6. PubMed ID: 16625854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical evidence supporting the Cortina criteria.
    von Werder K
    J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Cortina criteria for the diagnosis of acromegaly.
    degli Uberti EC; Bondanelli M; Ambrosio MR; Zatelli MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):70-2. PubMed ID: 16625849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
    Pokrajac A; Wark G; Ellis AR; Wear J; Wieringa GE; Trainer PJ
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
    Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of reference values for endocrine tests--part V: acromegaly.
    Endert E; van Rooden M; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2006; 64(7):230-5. PubMed ID: 16929084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical laboratory indices in the treatment of acromegaly.
    Clemmons DR
    Clin Chim Acta; 2011 Feb; 412(5-6):403-9. PubMed ID: 21075098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-I and mortality in patients with acromegaly.
    Strasburger CJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.